Decentralised testing, already commercial
This is the official investor hub for Atomo Diagnostics Limited. Everything we report sits here: results and financial reports, every ASX announcement, live market data, our product pipeline and the calendar of what is coming next.
Just released FY26 results: revenue up 41% to A$5.3 million, EBITDA improved 39%, debt free →FY26 results
A transitional year, with growth to show for it
Revenue grew 41% and our underlying EBITDA loss narrowed 39%, so more of each dollar of growth is now reaching the bottom line. Both of our established channels contributed, and we closed the year debt free.
Full year to 30 June 2026. Underlying EBITDA loss improved 39%, from A$3.38 million to A$2.06 million. Total cash receipts for the year were A$10.2 million.
Where our moat sits
If a test cannot be used correctly, its accuracy does not matter. Reliability is the product we sell.
This is why diagnostic companies buy our cassettes rather than build their own, and why regulators and public health buyers keep choosing our devices. Independent studies put the difference in numbers.
Our portfolio
Two revenue engines and a pipeline behind them
We sell our own finished tests and we supply our Pascal platform to other diagnostic companies. Both grew in FY26. Behind them, active syphilis has finished development and liver function has entered the pipeline, each running on hardware we have already validated.
Our own tests
Partner tests on our Pascal platform
Statuses as at our FY26 results, released 31 August 2026. Long term commercial supply agreements for Pascal with the Chromacare and UK programmes are anticipated early in FY27. Tests under consideration beyond this pipeline include fourth generation HIV, hepatitis B, hepatitis C, stroke and cardiac, each subject to commercial assessment.
Announcements that move our story forward
AT1 share price and market data
Current price
Volume
Market Cap.
Year low - high
Market data chart (ASX:AT1)
Volume traded
Share price ()
Last price
Open price
Day low - high
Price change
Percentage change
Previous close
Volume (no. of shares)
Turnover
Market cap
Shares outstanding
VWAP
Bid / Ask
52 week high
52 week low
Price/earnings ratio
Earnings per share
Stay close to the story
Never miss an Atomo announcement
Join our investor list and we will send our ASX announcements, quarterly results and webinar invitations straight to your inbox.
Talk to us
Investor contacts
Investor relations
Atomo Diagnostics Limited
Level 1, 3-5 George Street
Leichhardt NSW 2040
+61 2 9099 4750
investorqueries@atomodiagnostics.comShare registry
Boardroom Pty Limited
PO Box 3993
Sydney NSW 2001
1300 737 760
enquiries@boardroomlimited.com.au